Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T06:38:20.068Z Has data issue: false hasContentIssue false
  • English
  • Français

Dilated cardiomyopathy due to a phospholamban duplication

Published online by Cambridge University Press:  22 January 2014

Teresa M. Lee ,
Linda J. Addonizio  and
Wendy K. Chung
Teresa M. Lee
Affiliation:
Department of Pediatrics, Division of Cardiology, Columbia University Medical Center, New York, New York, United States of America
Linda J. Addonizio
Affiliation:
Department of Pediatrics, Division of Cardiology, Columbia University Medical Center, New York, New York, United States of America
Wendy K. Chung*
Affiliation:
Department of Pediatrics, Division of Molecular Genetics, Columbia University Medical Center, New York, New York, United States of America
*
Correspondence to: W. K. Chung, Department of Pediatrics, Division of Cardiology, Columbia University Medical Center, 1150 St. Nicholas Avenue, Room 620, New York, New York 10032, United States of America. Tel: 212-851-5315; E-mail: wkc15@columbia.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Dilated cardiomyopathy is characterised by dilation and impaired systolic function. We present the case of a child with dilated cardiomyopathy caused by a 624 kb duplication of 6q22.31, which includes the phospholamban gene. The patient also has failure to thrive and developmental delay due to complex cytogenetic abnormalities including a 5p15 deletion associated with Cri du Chat and an 11p15 duplication associated with Russell–Silver syndrome.

Keywords

Cardiomyopathydilatedphospholamban6q22.31
Type
Brief Reports
Information
Cardiology in the Young , Volume 24 , Issue 5 , October 2014 , pp. 953 - 954
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Taylor, MR, Carniel, E, Mestroni, L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1: 27.Google Scholar
2. Dellefave, L, McNally, EM. The genetics of dilated cardiomyopathy. Curr Opin Cardiol 2010; 25: 198–204.Google Scholar
3. Medin, M, Hermida-Prieto, M, Monserrat, L, et al. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 c>g mutation. Eur J Heart Fail 2007; 9: 37–43.Google Scholar
4. Schmitt, JP, Kamisago, M, Asahi, M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299: 1410–1413.Google Scholar
5. van der Zwaag, PA, van Rijsingen, IA, de Ruiter, R, et al. Recurrent and founder mutations in the netherlands-phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J 2013; 21: 286–293.Google Scholar
6. Lakdawala, NK, Funke, BH, Baxter, S, et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail 2012; 18: 296–303.Google Scholar
7. Minamisawa, S, Sato, Y, Tatsuguchi, Y, et al. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2003; 304: 1–4.Google Scholar